Status:
COMPLETED
Caffeine for Motor Manifestations of Parkinson's Disease
Lead Sponsor:
Ron Postuma
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Parkinson's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Numerous epidemiological studies have linked lifelong use of caffeine to a lower risk of Parkinson's disease (PD) - prospective studies have estimated that non-coffee drinkers have an approximately 1....
Detailed Description
Caffeine has been in widespread use for centuries, and is the commonest psychostimulant used worldwide. In Canada, estimates of mean daily intake for a 70 kg person range from 200-450 mg. The main sou...
Eligibility Criteria
Inclusion
- 1\. Subject has been diagnosed with idiopathic Parkinson's disease (stage I - IV Hoehn and Yahr)
Exclusion
- Estimated daily caffeine intake of more than 200 mg per day.
- Subject has dementia (MMSE \< 26/30) and ADL impairment secondary to cognitive loss, inability to understand consent process.
- Changes to antiparkinsonian medications in last 4 weeks or changes will be required during the period of the study protocol.
- Contraindication to caffeine use:
- Uncontrolled hypertension (systolic bp \>170 or diastolic bp \>110 on two consecutive readings)
- Use of lithium or clozapine
- Pre-menopausal women who are not using effective methods of birth control
- Current use of prescribed alerting agents such as modafinil and methylphenidate
- Active peptic ulcer disease
- Supraventricular cardiac arrhythmia
- Previous adverse reaction to caffeine which either required admission to hospital,or after which the patient was directly advised by a physician to not use caffeine.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01190735
Start Date
August 1 2010
End Date
February 1 2011
Last Update
April 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal General Hospital
Montreal, Quebec, Canada, H3G 1A4